2 completed, 1 not yet recruiting, 1 recruiting. 2 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow G-CSF (Granulocyte colony-stimulating factor): new trials by email Literature Review of G-CSF (Granulocyte colony-stimulating factor) trials Research Report on G-CSF (Granulocyte colony-stimulating factor)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer Sacituzumab Govitecan (SG), Atropine, G-CSF (Granulocyte colony-stimulating factor) - Breast Cancer, Advanced HR+/HER2- Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 30 | 2026-07-01 | 2026-01-28 |
| CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors G-CSF (Granulocyte colony-stimulating factor) - Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 160 | 2026-03-01 | 2026-06-29 |
| Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer CABAZITAXEL (XRP6258), Prednisone, Ciprofloxacin - Prostate Cancer | Phase 4 | Completed | Sanofi | 45 | 2012-07-01 | 2016-07-06 |
| 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) 2-CdA, Ara-C, G-CSF (Granulocyte colony-stimulating factor) - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 13 | 1998-03-01 | 2012-08-02 |
Breast Neoplasms (1) · Hypereosinophilic Syndrome (1) · Leukemia (1) · Prostatic Neoplasms (1)
First Affiliated Hospital of Zhejiang University (1) · M.D. Anderson Cancer Center (1) · MedSIR (1) · Sanofi (1)
Brazil (1) · China (1) · United States (1)
2025 (1)